When: Controlled pullback to $115-125 with MACD reset and declining volume

Then: Re-enter at structural support with reset momentum

TRIM TO 50-70% OF BENCHMARK WEIGHT WITH STOP AT 137

• ABBV playbook analogy is survivorship bias—Humira was ~40% of revenue with Skyrizi and Rinvoq already launched before LOE; Keytruda is ~50% of revenue with only 2 years to transition
• M&A spending ($25B deployed) does not equal successful integration—intangibles nearly doubled, equity declined by $10.7B in two quarters, $9.8B in new intangibles face clinical trial risk
• Leverage is real and underappreciated—$18.5B debt added in ~1 year (52% increase) against $15.2B FCF, with $8.5B dividend, $4B capex, and new debt service constraining flexibility
• Pipeline revenue math not refuted—$70B pipeline target yields $10-20B peak revenue in 5-8 years, far short of Keytruda contribution; no evidence provided that MRK oncology success rate exceeds industry average
• Near-term technical setup deteriorating—MACD crossing below signal with histogram at negative 1.14, price broke below 10 EMA at 148.21, RSI hasn't reached oversold extremes, August surge to 156.92 flagged as potential blow-off top
• Macro tail risks not fully appreciated—geopolitical energy shock priced at 9% probability by end of September, CPI release upcoming with Fed locked out of cutting, real rates rising
• Valuation offers no margin of safety—forward P/E 15x, PEG ratio 2.93 (flagged as modestly elevated), stock near 52-week highs, TTM P/E 115x pricing in normalized earnings of $9.55
• Downside from 156 high to 50 SMA at 135.67 represents ~25% drawdown; at full benchmark weight this is significant NAV impairment versus contained risk at 50-70% weight

→ vs aggressive: ABBV playbook claim is survivorship bias—MRK's Keytruda exposure (~50% of revenue) with 2 years to LOE is materially different from ABBV's pre-biosimilar Humira situation

Trim MRK to 60-70% of benchmark weight with stop at $135

• Neutral analyst endorses trader's trim direction but finds 50-70% slightly too aggressive; settles on 60-70% as balanced
• Aggressive analyst's 'bear case in price' claim is intellectually questionable given 7.5% decline from 52-week high vs 79% gain from low
• Conservative analyst cherry-picks Pfizer/Gilead failures while ignoring MRK's diversified portfolio and demonstrated franchise-launch capability
• Net debt of $47B against $15B annual FCF is elevated but within normal range for pharma transformation, not a distressed balance sheet
• $9.8B in new intangibles represents productive acquired assets, not operational deterioration; forward P/E of 15x reflects market understanding of transition period
• Pipeline is real but unproven; M&A strategy is rational but execution-dependent; market pricing base case of moderate success
• Technical deterioration is real: MACD crossed below signal, price below 10 EMA, though 200 SMA trend remains intact
• Stop at $135 is reasonable given 50 SMA support at $135.67 and lower Bollinger at $134.35; recommend widening slightly to avoid whipsaw
• Defensive positioning appropriate pending CPI print, but MRK's defensive characteristics justify continued participation rather than full exit

→ vs aggressive: Calls 'bear case already in price' intellectually questionable given stock is 7.5% below 52-week high but up 79% from 52-week low; forward P/E of 15x prices in successful integration, not failure

→ vs aggressive: Leverage argument 'technically true but practically meaningless'; zeroing dividend to deleverage during patent cliff transition is not how pharma management operates

→ vs aggressive: Six-month trend structure doesn't justify ignoring near-term deterioration; MACD crossed below signal and price below 10 EMA; using long-term framing to dismiss short-term signals is misleading

→ vs conservative: Survivorship bias: cherry-picks Pfizer and Gilead failures while ignoring MRK's track record of successful integrations and diversified portfolio unlike Gilead's single-therapeutic-area dependency

→ vs conservative: Mischaracterizes leverage as 'elevated'; $47B net debt against $15B annual FCF with 1.32 current ratio and investment-grade access is at upper end of MRK's historical range but within normal for pharma transformation

→ vs conservative: 60-70% of benchmark weight is standard portfolio management, not maximum defensive posture; framing it as such lets perfect be the enemy of good

→ vs conservative: Shouldn't reduce MRK exposure aggressively for macro reasons when MRK's defensive characteristics are precisely what provide downside protection in risk-off environment